CNK-UT009 Cell Therapy Starts A Phase-I Clinical Trial

CNK-UT009, as tested here, is a one-time infusion of living cells designed to modify the immune system’s behavior. The idea behind it is that by reprogramming T cells, it may be possible to suppress the misdirected immune response that causes type 1 diabetes while potentially allowing remaining beta cells to function better. Animal studies suggest that this method could reduce autoimmunity and…